Advisory: Alert on Innovent Biologics Phase 3 study results withdrawn
Today 12:14
ADVISORY-Alert on Innovent Biologics Phase 3 study results withdrawn An alert on Innovent Biologics 1801.HK announcing Phase 3 study results of arcotatug tavatecan in gastric cancer has been withdrawn after the company clarified that the release should be disregarded.
There will be no substitute.
STORY_NUMBER: nTUA18F3RH
STORY_DATE: October 23, 2026
STORY_TIME: 10:10 AM GMT
Recent news on Innovent Biologics
See all newsAdvisory: Alert on Innovent Biologics Phase 3 study results withdrawn
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals